@Investinc_Intel What people are also not accounting for is that there is medication revenue + membership revenue and that the membership fee is almost entirely pure profit.
@aleabitoreddit@yoy_returns ... they argue that this is driven by a learning mechansims that is esp. relevant for experience goods with high(er) uncertainty. 1) A large current user base acts as a signal of quality, inducing a "herding effect". 2) Current users share WOM influencing future users choices.
@aleabitoreddit@yoy_returns There are network effects, although not in the same way as on social networks. Zhou et al. (2024) argue that user stickiness on platforms is driven by "cross-period same-side" network effects. This will be relevant for peptides as there is high(er) uncertainty around them.
@himshouse@edwrdmoreno Here is why Hims wants Novo to sue them: If Hims wins the case, the litigation risk vanishes. If Hims loses, they still win. Then they position themselves as the Robin Hood of healthcare. It's the Robinhood playbook! But Novo won't sue; there is too much at stake for them.
@EndicottInvests Great analysis. Finally someone who understands what is happening! ๐๐ป I would add that the main reason why competitor cannot follow is high switching costs for customers.